À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå ¿¹Ãø : Áö¿ªº° ºÐ¼®-Ä¡·á À¯Çüº°, Áõ»óº°, ÃÖÁ¾ »ç¿ëÀÚº°(-2030³â)
Europe Hyperpigmentation Disorder Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type, Condition, and End User
À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀåÀº 2022³â¿¡ 11¾ï 99¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 19¾ï 1,195¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2022³âºÎÅÍ 2030³â±îÁö CAGRÀº 7.1%·Î ÃßÁ¤µË´Ï´Ù.
»ö¼ÒÄ§ÂøÁõ °è¹ß ÇÁ·Î±×·¥ Áõ°¡°¡ À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀåÀ» °ßÀÎ
Àڿܼ±¿¡ ÀÇÇØ À¯¹ßµÇ´Â ÇǺÎÀÇ »ö¼ÒÄ§Âø¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ´Â Ä·ÆäÀÎÀº ÀÌ·¯ÇÑ Áúº´ÀÇ ¿¹¹æ, ½ºÅ©¸®´×, Áø´Ü ¹× Ä¡·á¿¡ ´ëÇÑ ÀÏ¹Ý ½Ã¹ÎÀ» ±³À°ÇÏ´Â µ¥ ÇʼöÀûÀ̸ç ÀÌ·¯ÇÑ Áúº´À» °ü¸®Çϱâ À§ÇØ ¾çÁúÀÇ Àڿܼ± Â÷´ÜÁ¦ Á¦Ç° »ç¿ëÀÇ Á߿伺¿¡ ´ëÇØ¼µµ ³íÀǵ˴ϴÙ.
2022³â 5¿ù 25ÀÏ, Bella Aurora´Â ±¹Á¦ »ö¼ÒÄ§ÂøÀÇ ³¯À» ÃàÇÏÇß½À´Ï´Ù. ÇǺΠ»ö¼ÒÄ§ÂøÀÇ Á¶»ç¿¡ ´ëÇØ 130³â ÀÌ»óÀÇ °æÇèÀ» °¡Áö´Â Bella Aurora´Â, ½ºÆäÀΰú ÀÌÅ»¸®¾Æ Àü¿ªÀÇ Àú¸íÇÑ ÇǺΰú ÀÇ»ç, ¾à»ç, ¿ÀÇǴϾ𠸮´õÀÇ Áö¿øÀ» ¹Þ¾Æ, ÀÌ ³¯À» ÃàÇÏÇÏ´Â ±¹Á¦ÀûÀÎ °è¹ß Ä·ÆäÀÎÀ» °³½ÃÇß½À´Ï´Ù. 2021³â 6¿ù ´õ¸ô·ÎÁöÄ« Ŭ·¹¸£´Â ÇǺΠ¼ö¿ëÀ» ÃËÁøÇÏ°í ¿°Áõ ÈÄ »ö¼ÒÄ§Âø, ¿©µå¸§, ¿¬¼³ µî¿¡ ´ëÇØ ûÁßÀ» ±³À°ÇÏ´Â Ä·ÆäÀÎÀ» ½ÃÀÛÇß½À´Ï´Ù.
°£¹Ý ¹× ±âŸ »ö¼ÒÄ§Âø Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡´Â Çõ½ÅÀûÀ̰í È¿°úÀûÀÎ Ä¡·á Á¦Ç°°ú Ä¡·á¿¡ ´ëÇÑ ¼ö¿äÀÇ ±ÞÁõÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ »çȸ°¡ »ö¼ÒÄ§ÂøÀ» ¾î¶»°Ô ÀÌÇØÇÏ°í ¾î¶»°Ô ´ëóÇϴ°¡ ÇÏ´Â Á¡¿¡ À־µ, Áß¿äÇÏ°í ±àÁ¤ÀûÀÎ º¯È°¡ ÃÊ·¡µÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼ °è¹ß ÇÁ·Î±×·¥ÀÇ Áõ°¡°¡ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå °³¿ä
À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. 2023³â À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå Á¡À¯À²Àº µ¶ÀÏÀÌ ÃÖ´ë¿´½À´Ï´Ù. ±¹¹Îµé »çÀÌ¿¡¼ ½ºÅ²Äɾ ÇǺΰú °Ç°¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁ® Áß½ÃµÇ°Ô µÈ °Í µîÀÌ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. µ¶ÀÏÀÎÀº °£¹Ý, ³ëÀιÝ, ¿°ÁõÈÄ »ö¼ÒÄ§Âø µîÀÇ »ö¼ÒÄ§Âø Àå¾Ö¿¡ óºÐÀ» À§ÇÑ Ã·´Ü ½ºÅ²ÄÉ¾î ¼Ö·ç¼ÇÀ» Ãß±¸ÇÏ´Â µ¥ Á¡Á¡ ´õ Àû±ØÀûÀ¸·Î ´ëóÇϰí ÀÖÀ¸¸ç ½ÃÀå¿¡¼ Çõ½ÅÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. °í·ÉÈ Àα¸°¡ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ »ö¼ÒÄ§ÂøÀ» ºñ·ÔÇÑ ³ëÈ¿Í °ü·ÃµÈ ÇǺΠ°í¹ÎÀÌ ¸¹ÀÌ ¹ß»ýÇϰí ÀÖÀ¸¸ç, ºû³ª´Â ÇǺθ¦ À¯ÁöÇϱâ À§ÇØ Àü¹®ÀûÀÎ Ä¡·á¸¦ ¿ä±¸ÇÏ´Â »ç¶÷ÀÌ ´Ã°í ÀÖ½À´Ï´Ù. µ¶ÀÏ ¿¬¹æÅë°è±¹(Statistisches Bundesamt)¿¡ µû¸£¸é 67¼¼ ÀÌ»óÀÇ Àα¸´Â 2030³â´ë Á߹ݱîÁö 400¸¸ ¸í¿¡¼ Àû¾îµµ 2,000¸¸ ¸íÀ¸·Î Áõ°¡ÇÑ´Ù°í ÇÕ´Ï´Ù. ½ºÅ²Äɾî¿Í ¾ÈƼ¿¡ÀÌ¡ÀÇ ÇØ°áÃ¥À» Áß½ÃÇÏ´Â ¹®È´Â Àα¸ÀÇ °í·ÉÈ¿Í ³ôÀº ÇǺκ´ À¯º´·ü°ú ¸Â¹°·Á µ¶ÀÏ¿¡¼ »ö¼ÒÄ§ÂøÁõ Ä¡·á ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ´õ¿íÀÌ ¿Ü¸ð¿¡ ´ëÇÑ °ü½É°ú ¿ì·ÁÀÇ Áõ°¡´Â ´Ù¾çÇÑ ¹Ì¿ë½Ã¼úÀÇ ¼ö¿ä¸¦ Áõ´ë½ÃŰ´Â Áß¿äÇÑ ¿äÀÎÀ¸·Î Áö¼ÓÀûÀ¸·Î ½ÃÀåÀÇ °·ÂÇÑ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¶ÀÏ¿¡´Â °íµµÀÇ ÀÇ·á ÀÎÇÁ¶ó, ¼÷·ÃµÈ ÇǺΰú ÀÇ»ç, ÆòÆÇÀÌ ³ôÀº ¹Ì¿ë Ŭ¸®´ÐÀÌ Á¸ÀçÇϱ⠶§¹®¿¡ Æø³ÐÀº »ö¼ÒÄ§Âø Ä¡·á¿Í ½Ã¼úÀ» ¹Þ±â ½±°í Áú ³ôÀº ÇǺΠ°ü¸® ¼ºñ½º¸¦ ¿øÇÏ´Â ±¹³»¿Ü ȯÀÚµéÀ» ²ø¾îµéÀ̰í ÀÖ½À´Ï´Ù.
À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(´ÜÀ§ : 100¸¸ ´Þ·¯)(-2030³â)
À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀåÀÇ ¼¼ºÐÈ
À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀåÀº Ä¡·á À¯Çüº°, Áõ»óº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.
Ä¡·á À¯Çüº°·Î º¸¸é, À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀåÀº ÄÚ½º¸Þ½´Æ¼ÄÃ, ±¤¼± ¹× ·¹ÀÌÀú Ä¡·á, ¹Ì¼¼¹ÚÇǼú, ÄɹÌÄà Çʸµ, ³Ãµ¿¿ä¹ý, ±âŸ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â ÄÚ½º¸Þ½´Æ¼Äà ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
Áõ»óº°·Î º¸¸é À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀåÀº °£¹Ý, ÈæÁ¡, ¿°Áõ ÈÄ »ö¼ÒÄ§Âø µîÀ¸·Î ±¸ºÐµË´Ï´Ù. °£¹Ý ºÎ¹®Àº 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚº°·Î º¸¸é À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀåÀº º´¿ø, ÇǺΰú ¼¾ÅÍ, ±âŸ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. º´¿ø ºÎ¹®Àº 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. µ¶ÀÏÀº 2022³â À¯·´ »ö¼ÒÄ§Âø Ä¡·á ½ÃÀå Á¡À¯À²À» µ¶Á¡Çß½À´Ï´Ù.
AbbVie Inc, Bayer AG, EpiPharm AG, Galderma SA, L'OREAL SA, Lutronic Co Ltd, Obagi Cosmeceuticals LLC, Pierre Fabre SA µîÀÌ À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¶»ç ¹æ¹ý
Á¦4Àå À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ
- À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- °£¹ÝÀÇ À¯º´·ü »ó½Â
- »ö¼ÒÄ§ÂøÁõ °è¹ß ÇÁ·Î±×·¥ Áõ°¡
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- ½ÃÀå ±âȸ
- ½ÃÀå ÁøÃâ±â¾÷ÀÇ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
- ÇâÈÄÀÇ µ¿Çâ
- ÀýÁ¦ ·¹ÀÌÀúÀÇ »ç¿ë
- PATH-3 ±â¼ú¿¡ ±Ù°ÅÇÑ ½ÅÁ¦Ç°
- ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ
Á¦5Àå À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå ºÐ¼®
- À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå ¼öÀÍ(2020-2030³â)
Á¦6Àå À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°
- ÈÀåǰ ½´Æ¼ÄÃ
- ±¤¼± ¹× ·¹ÀÌÀú ¿ä¹ý
- ¹Ì¼¼¹ÚÇǼú
- ÄɹÌÄà Çʸµ
- µ¿°á¿ä¹ý
- ±âŸ
Á¦7Àå À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå ºÐ¼® : Áõ»óº°
- °£¹Ý
- ÈæÁ¡
- ¿°Áõ ÈÄ »ö¼Ò Ä§Âø
- ±âŸ
Á¦8Àå À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚº°
Á¦9Àå À¯·´ÀÇ »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå : ±¹°¡º° ºÐ¼®
- µ¶ÀÏ
- ¿µ±¹
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ±âŸ À¯·´
Á¦10Àå »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀå : ¾÷°è Á¤¼¼
- »ö¼ÒÄ§ÂøÁõ Ä¡·á ½ÃÀåÀÇ ¼ºÀå Àü·«
- À¯±âÀû ¼ºÀå Àü·«
- ¹«±âÀû ¼ºÀå Àü·«
Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ
- AbbVie Inc
- EpiPharm AG
- Galderma SA
- Obagi Cosmeceuticals LLC
- Bayer AG
- Lutronic Co Ltd
- L'OREAL SA
- Pierre Fabre SA
Á¦12Àå ºÎ·Ï
AJY
The Europe hyperpigmentation disorder treatment market was valued at US$ 1,100.99 million in 2022 and is expected to reach US$ 1,911.95 million by 2030; it is estimated to register a CAGR of 7.1% from 2022 to 2030.
Increasing Number of Hyperpigmentation Disorder Awareness Programs Drives Europe Hyperpigmentation Disorder Treatment Market
Campaigns to raise awareness about UV-induced skin hyperpigmentation are essential to educate the general populace on the prevention, screening, diagnosis, and treatment of these conditions; they also discuss the importance of using good-quality sunscreen products to manage these disorders.
On May 25, 2022, Bella Aurora celebrated the International Skin Pigmentation Day. With over 130 years of experience in the research of skin pigmentation, Bella Aurora launched an international awareness campaign to celebrate the day with the support of renowned dermatologists, pharmacists, and key opinion leaders across the Spain and Italy. In June 2021, Dermalogica Clear launched a campaign to encourage skin acceptance and educate audiences on post-inflammatory hyperpigmentation, acne, breakouts, and more.
The increased awareness of melasma and other hyperpigmentation disorders has led to a surge in demand for innovative and efficacious treatment products and procedures. Moreover, it has brought about a significant and positive change in how society understands and manages hyperpigmentation. Thus, the increasing number of awareness programs bolsters the growth of the hyperpigmentation disorder treatment market.
Europe Hyperpigmentation Disorder Treatment Market Overview
The hyperpigmentation disorder treatment market in Europe is segmented into Germany, UK, France, Italy, Spain, and Rest of Europe. The Germany held the largest Europe hyperpigmentation disorder treatment market share in 2023. Factors such as increasing awareness and emphasis on skincare and dermatological health among the population driving the market growth. Germans are increasingly proactive in seeking advanced skincare solutions to address hyperpigmentation disorders such as melasma, age spots, and post-inflammatory hyperpigmentation, driving the demand for innovative treatments in the market. Additionally, the rise in the aging population in Germany has led to numerous age-related skin concerns, including hyperpigmentation, prompting individuals to seek specialized treatments to maintain radiant skin. According to the Federal Statistical Office of Germany (Statistisches Bundesamt), the number of people aged 67 and above would increase from 4 million to at least 20 million by the mid-2030s. A culture that values skin care and anti-aging solutions, coupled with population aging and high skin disease prevalence, contributes to the demand for hyperpigmentation disorder treatments in Germany. Furthermore, rising attention and concerns about appearance continue to be a key factor in increasing the demand for various cosmetic procedures, contributing to strong market growth. Moreover, the presence of advanced medical infrastructure, skilled dermatologists, and reputable cosmetic clinics in Germany contributes to the accessibility of a wide range of hyperpigmentation treatments and procedures, attracting both domestic and international patients seeking quality skin care services.
Europe Hyperpigmentation Disorder Treatment Market Revenue and Forecast to 2030 (US$ Million)
Europe Hyperpigmentation Disorder Treatment Market Segmentation
The Europe hyperpigmentation disorder treatment market is categorized into treatment type, condition, end user, and country.
Based on treatment type, the Europe hyperpigmentation disorder treatment market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held the largest market share in 2022.
Based on condition, the Europe hyperpigmentation disorder treatment market is segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held the largest market share in 2022.
Based on end user, the Europe hyperpigmentation disorder treatment market is segmented into hospitals, dermatology centers, and others. The hospitals segment held the largest market share in 2022.
By country, the Europe hyperpigmentation disorder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe hyperpigmentation disorder treatment market share in 2022.
AbbVie Inc, Bayer AG, EpiPharm AG, Galderma SA, L'OREAL S.A., Lutronic Co Ltd, Obagi Cosmeceuticals LLC, and Pierre Fabre SA are some of the leading companies operating in the Europe hyperpigmentation disorder treatment market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. Europe Hyperpigmentation Disorder Treatment Market - Key Market Dynamics
- 4.1 Europe Hyperpigmentation Disorder Treatment Market - Key Market Dynamics
- 4.2 Market Drivers
- 4.2.1 Rise in Prevalence of Melasma
- 4.2.2 Increasing Number of Hyperpigmentation Disorder Awareness Programs
- 4.3 Market Restraints
- 4.3.1 High Cost of Treatments
- 4.4 Market Opportunities
- 4.4.1 Strategic Initiatives by Market Players
- 4.5 Future Trends
- 4.5.1 Use of Ablative Lasers
- 4.5.2 Novel Products Based on PATH-3 Technology
- 4.6 Impact of Drivers and Restraints:
5. Hyperpigmentation Disorder Treatment Market - Europe Analysis
- 5.1 Europe Hyperpigmentation Disorder Treatment Market Revenue (US$ Million), 2020-2030
6. Europe Hyperpigmentation Disorder Treatment Market Analysis - by Treatment Type
- 6.1 Cosmeceutical
- 6.1.1 Overview
- 6.1.2 Cosmeceutical: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 6.2 Light or Laser Therapy
- 6.2.1 Overview
- 6.2.2 Light or Laser Therapy: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 6.3 Microdermabrasion
- 6.3.1 Overview
- 6.3.2 Microdermabrasion: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4 Chemical Peels
- 6.4.1 Overview
- 6.4.2 Chemical Peels: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 6.5 Cryotherapy
- 6.5.1 Overview
- 6.5.2 Cryotherapy: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7. Europe Hyperpigmentation Disorder Treatment Market Analysis - by Condition
- 7.1 Melasma
- 7.1.1 Overview
- 7.1.2 Melasma: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.2 Solar Lentigines
- 7.2.1 Overview
- 7.2.2 Solar Lentigines: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.3 Post-inflammatory Hyperpigmentation
- 7.3.1 Overview
- 7.3.2 Post-inflammatory Hyperpigmentation: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Hyperpigmentation Disorder Treatment Market Analysis - by End User
- 8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Hospitals: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 8.2 Dermatology Centers
- 8.2.1 Overview
- 8.2.2 Dermatology Centers: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Hyperpigmentation Disorder Treatment Market - Country Analysis
- 9.1 Europe Hyperpigmentation Disorder Treatment Market
- 9.1.1 Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast Analysis - by Country
- 9.1.1.1 Europe Hyperpigmentation Disorder Treatment Market - Revenue and Forecast Analysis - by Country
- 9.1.1.2 Germany
- 9.1.1.3 Germany: Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.3.1 Germany: Hyperpigmentation Disorder Treatment Market Breakdown, by Treatment Type
- 9.1.1.3.2 Germany: Hyperpigmentation Disorder Treatment Market Breakdown, by Condition
- 9.1.1.3.3 Germany: Hyperpigmentation Disorder Treatment Market Breakdown, by End User
- 9.1.1.4 UK
- 9.1.1.5 UK: Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.5.1 UK: Hyperpigmentation Disorder Treatment Market Breakdown, by Treatment Type
- 9.1.1.5.2 UK: Hyperpigmentation Disorder Treatment Market Breakdown, by Condition
- 9.1.1.5.3 UK: Hyperpigmentation Disorder Treatment Market Breakdown, by End User
- 9.1.1.6 France
- 9.1.1.7 France: Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.7.1 France: Hyperpigmentation Disorder Treatment Market Breakdown, by Treatment Type
- 9.1.1.7.2 France: Hyperpigmentation Disorder Treatment Market Breakdown, by Condition
- 9.1.1.7.3 France: Hyperpigmentation Disorder Treatment Market Breakdown, by End User
- 9.1.1.8 Italy
- 9.1.1.9 Italy: Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.9.1 Italy: Hyperpigmentation Disorder Treatment Market Breakdown, by Treatment Type
- 9.1.1.9.2 Italy: Hyperpigmentation Disorder Treatment Market Breakdown, by Condition
- 9.1.1.9.3 Italy: Hyperpigmentation Disorder Treatment Market Breakdown, by End User
- 9.1.1.10 Spain
- 9.1.1.11 Spain: Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.11.1 Spain: Hyperpigmentation Disorder Treatment Market Breakdown, by Treatment Type
- 9.1.1.11.2 Spain: Hyperpigmentation Disorder Treatment Market Breakdown, by Condition
- 9.1.1.11.3 Spain: Hyperpigmentation Disorder Treatment Market Breakdown, by End User
- 9.1.1.12 Rest of Europe
- 9.1.1.13 Rest of Europe: Hyperpigmentation Disorder Treatment Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.1.13.1 Rest of Europe: Hyperpigmentation Disorder Treatment Market Breakdown, by Treatment Type
- 9.1.1.13.2 Rest of Europe: Hyperpigmentation Disorder Treatment Market Breakdown, by Condition
- 9.1.1.13.3 Rest of Europe: Hyperpigmentation Disorder Treatment Market Breakdown, by End User
10. Hyperpigmentation Disorder Treatment Market - Industry Landscape
- 10.1 Overview
- 10.2 Growth Strategies in Hyperpigmentation Disorder Treatment Market
- 10.3 Organic Growth Strategies
- 10.4 Inorganic Growth Strategies
11. Company Profiles
- 11.1 AbbVie Inc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
- 11.2 EpiPharm AG
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
- 11.3 Galderma SA
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
- 11.4 Obagi Cosmeceuticals LLC
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
- 11.5 Bayer AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
- 11.6 Lutronic Co Ltd
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
- 11.7 L'OREAL S.A.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
- 11.8 Pierre Fabre SA
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
12. Appendix
- 12.1 About The Insight Partners
- 12.2 Glossary of Terms